Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

The herbal weight loss supplement Que She, advertised as “Slimming Factor Capsule” and as “an all-natural blend of Chinese herbs,” widely distributed on Internet sites such as the Bouncing Bear Botanicals website and at retail outlets such as Sacred Journey in Lawrence, Kansas, has been found to contain ingredients that can cause serious harm to consumers, according to an analysis conducted by the Food and Drug Administration (FDA).

Read the rest of this entry »

The Food and Drug Administration (FDA) is reviewing data from two clinical trials that suggest the blood pressure medication Benicar (olmesartan) may increase the risk of death from cardiovascular causes in patients with type 2 diabetes, according to an FDA safety announcement. The agency is continuing to review the data from two studies, ROADMAP and ORIENT, and is considering additional ways to asses the cardiovascular effects of Benicar.

Read the rest of this entry »

A medication primarily used to treat men with prostate cancer has been associated with a slightly increased risk for diabetes, heart attack, stroke and sudden death. The findings are preliminary and are part of an ongoing analysis of several studies by the Food and Drug Administration (FDA).

Read the rest of this entry »

At least 250 people – 50 more than previously identified – have been exposed to excess radiation of up to eight times the expected level during CT perfusion scans, causing hair loss and skin redness, and putting them at risk of some forms of cancer, according to Food and Drug Administration (FDA) safety investigation.

Read the rest of this entry »

Off-label marketing is an illegal yet commonly employed sales strategy that some big pharmaceutical companies practice to broaden the appeal of a drug and boost sales. One of the most blatant examples of off-label marketing involved Bayer Healthcare’s blockbuster birth control pill Yaz. Bayer promoted the drug as a treatment for premenstrual dysphoric disorder (PMDD) symptoms and to clear up moderate cases of acne when the FDA approved it as birth control only. Bayer stopped the deceptive marketing of Yaz when the FDA cited it for false and misleading advertising.

Read the rest of this entry »

Patients at an unidentified facility who received perfusion CT imaging performed to aid in the diagnosis of stroke accidentally received radiation doses approximately eight times the expected level, putting patients at increased risk for long-term radiation effects, the Food and Drug Administration (FDA) announced. Over an 18-month period, 206 patients at the one facility involved received the radiation overdoses to the head. In some cases, this excessive dose resulted in hair loss and erythema. The facility has notified all patients who received the overexposure and provided resources for additional information.

Read the rest of this entry »